Insulet Corporation (NASDAQ: PODD) reported Q3 sales of $432.7 million, up 27.0%, or 25.1% in constant currency, beating the consensus of $414.383 million.
Total Omnipod revenue of $422 million marked a year-over-year increase of 29.4%.
The company reported adjusted EPS of $0.71, beating the consensus of $0.40 and higher than $0.45 a year ago.
"Our third quarter financial and operational results marked another strong quarter for Insulet, and as a result of continued high demand for Omnipod 5 – both in the U.S. and globally – we are pleased to again raise ...